The partner Coriolis Pharma Research GmbH is responsible for formulation development, analytical development and stability testing to support thepre- clinical and clinical development of Anticalins. The aim is obtaining stable, patient-friendly Anticalin formulations for parenteral application (i.v. or s.c. injection) suitable for clinical development and final admission to the market.

Coriolis Pharma is a SME operating as an independent service provider for research and development of biopharmaceutical drugs and vaccines (proteins, monoclonal antibodies, peptides, RNA/DNA, liposomes, nanoparticles). Coriolis Pharma has been founded in April 2008 as spin-off company of the Department of Pharmaceutical Technology and Biopharmaceutics of the Ludwig- Maximilians University Munich, Germany. The facilities of Coriolis Pharma are located in the Innovation and Start-Up Center for Biotechnology (IZB) in Martinsried/ Munich, Germany. Coriolis Pharma is equipped with state-of-the-art technology for formulation manufacturing, lyophilization, sterile manufacturing and analytics (protein characterization, stability testing, aggregate and particle analytics, physico-chemical characterization of lyophilized formulations). Currently, the company has 18 employees and is supported by a scientific advisory board (Prof. Dr. G. Winter, Prof. Dr. W. Friess, Prof. Dr. W. Jiskoot).

Key expertise of Coriolis Pharma relevant for the project is: (i) formulation research and development, (ii) analytical development, (iii) process development (sterile manufacturing, lyophilization) and (iv) stability testing for biopharmaceutical drugs and vaccines, with focus on therapeutic proteins. Several liquid and lyophilized formulations for the parenteral application therapeutic proteins developed at Coriolis Pharma have successfully been approved by the authorities and are currently used in clinical phases I-III. Also relevant for the project is also the experience in the field of highly concentrated protein formulations and the corresponding analytical characterization. Coriolis Pharma is also performing own research in the field of formulation, analytics and process development of biopharmaceutical drugs and vaccines.

For more information, please contact:
Michael Wiggenhorn
Coriolis PharmaService GmbH
Am Klopferspitz 19
82152 Martinsried
Germany
Telefon +49 (0) 89 54 24 49 8-0
email: Michael.Wiggenhorn "at" coriolis-pharma.com